Bioadhesive delivery systems for mucosal vaccine delivery

References

• Agostinis F, Tellarini L, Canonica GW, Falagiani P, Passalacqua G. (2005). Safety of sublingual immunotherapy with a monomeric allergoid in very young children. Allergy, 60, 133.
   PubMed Web of Science ®Google Scholar
• Allaoui-Attarki K, Pecquet S, Fattal E, Trollé S, Chachaty E, Couvreur P, Andremont A. (1997). Protective immunity against Salmonella typhimurium elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly(DL-lactide-co-glycolide) microspheres. Infect Immun, 65, 853–857.
   PubMed Web of Science ®Google Scholar
• Amidi M, Mastrobattista E, Jiskoot W, Hennink WE. (2010). Chitosan-based delivery systems for protein therapeutics and antigens. Adv Drug Deliv Rev, 62, 59–82.
   PubMed Web of Science ®Google Scholar
• André FE. (2003). Vaccinology: past achievements, present roadblocks and future promises. Vaccine, 21, 593–595.
   PubMed Web of Science ®Google Scholar
• Arca HC, Günbeyaz M, Senel S. (2009). Chitosan-based systems for the delivery of vaccine antigens. Expert Rev Vaccines, 8, 937–953.
   PubMed Web of Science ®Google Scholar
• Armstrong ME, Lavelle EC, Loscher CE, Lynch MA, Mills KH. (2005). Proinflammatory responses in the murine brain after intranasal delivery of cholera toxin: implications for the use of AB toxins as adjuvants in intranasal vaccines. J Infect Dis, 192, 1628–1633.
   PubMed Web of Science ®Google Scholar
• Aspden TJ, Mason JD, Jones NS, Lowe J, Skaugrud O, Illum L. (1997). Chitosan as a nasal delivery system: the effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers. J Pharm Sci, 86, 509–513.
   PubMed Web of Science ®Google Scholar
• Baca-Estrada ME, Foldvari M, Snider M. (1999). Induction of mucosal immune responses by administration of liposome-antigen formulations and interleukin-12. J Interferon Cytokine Res, 19, 455–462.
   PubMed Web of Science ®Google Scholar
• Barackman JD, Ott G, O’Hagan DT. (1999). Intranasal immunization of mice with influenza vaccine in combination with the adjuvant LT-R72 induces potent mucosal and serum immunity which is stronger than that with traditional intramuscular immunization. Infect Immun, 67, 4276–4279.
   PubMed Web of Science ®Google Scholar
• Baudner BC, Giuliani MM, Verhoef JC, Rappuoli R, Junginger HE, Giudice GD. (2003). The concomitant use of the LTK63 mucosal adjuvant and of chitosan-based delivery system enhances the immunogenicity and efficacy of intranasally administered vaccines. Vaccine, 21, 3837–3844.
   PubMed Web of Science ®Google Scholar
• Baudner BC, Morandi M, Giuliani MM, Verhoef JC, Junginger HE, Costantino P, Rappuoli R, Del Giudice G. (2004). Modulation of immune response to group C meningococcal conjugate vaccine given intranasally to mice together with the LTK63 mucosal adjuvant and the trimethyl chitosan delivery system. J Infect Dis, 189, 828–832.
   PubMed Web of Science ®Google Scholar
• Belshe R, Lee MS, Walker RE, Stoddard J, Mendelman PM. (2004). Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine. Expert Rev Vaccines, 3, 643–654.
   PubMedGoogle Scholar
• BenMohamed L, Belkaid Y, Loing E, Brahimi K, Gras-Masse H, Druilhe P. (2002). Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant. Eur J Immunol, 32, 2274–2281.
   PubMed Web of Science ®Google Scholar
• Bernkop-Schnürch A, Walker G. (2001). Multifunctional matrices for oral peptide delivery. Crit Rev Ther Drug Carrier Syst, 18, 459–501.
   PubMed Web of Science ®Google Scholar
• Bivas-Benita M, van Meijgaarden KE, Franken KL, Junginger HE, Borchard G, Ottenhoff TH, Geluk A. (2004). Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A*0201-restricted T-cell epitopes of Mycobacterium tuberculosis. Vaccine, 22, 1609–1615.
   PubMed Web of Science ®Google Scholar
• Borges O, Cordeiro-da-Silva A, Tavares J, Santarém N, de Sousa A, Borchard G, Junginger HE. (2008). Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles. Eur J Pharm Biopharm, 69, 405–416.
   PubMed Web of Science ®Google Scholar
• Borges O, Tavares J, de Sousa A, Borchard G, Junginger HE, Cordeiro-da-Silva A. (2007). Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles. Eur J Pharm Sci, 32, 278–290.
   PubMed Web of Science ®Google Scholar
• Brandtzaeg P, Farstad IN, Johansen FE, Morton HC, Norderhaug IN, Yamanaka T. (1999). The B-cell system of human mucosae and exocrine glands. Immunol Rev, 171, 45–87.
   PubMed Web of Science ®Google Scholar
• Brandtzaeg P. (2007). Induction of secretory immunity and memory at mucosal surfaces. Vaccine, 25, 5467–5484.
   PubMed Web of Science ®Google Scholar
• Brandtzaeg P. (2009). Mucosal immunity: induction, dissemination, and effector functions. Scand J Immunol, 70, 505–515.
   PubMed Web of Science ®Google Scholar
• Brayden DJ, Jepson MA, Baird AW. (2005). Keynote review: intestinal Peyer’s patch M cells and oral vaccine targeting. Drug Discov Today, 10, 1145–1157.
   PubMed Web of Science ®Google Scholar
• Brayden DJ. (2001). Oral vaccination in man using antigens in particles: current status. Eur J Pharm Sci, 14, 183–189.
   PubMed Web of Science ®Google Scholar
• Cahill ES, O’Hagan DT, Illum L, Barnard A, Mills KH, Redhead K. (1995). Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles. Vaccine, 13, 455–462.
   PubMed Web of Science ®Google Scholar
• Calinescu C, Mulhbacher J, Nadeau E, Fairbrother JM, Mateescu MA. (2005). Carboxymethyl high amylose starch (CM-HAS) as excipient for Escherichia coli oral formulations. Eur J Pharm Biopharm, 60, 53–60.
   PubMed Web of Science ®Google Scholar
• Campoccia D, Doherty P, Radice M, Brun P, Abatangelo G, Williams DF. (1998). Semisynthetic resorbable materials from hyaluronan esterification. Biomaterials, 19, 2101–2127.
   PubMed Web of Science ®Google Scholar
• Capozzo AV, Cuberos L, Levine MM, Pasetti MF. (2004). Mucosally delivered Salmonella live vector vaccines elicit potent immune responses against a foreign antigen in neonatal mice born to naive and immune mothers. Infect Immun, 72, 4637–4646.
   PubMed Web of Science ®Google Scholar
• Cesta MF. (2006). Normal structure, function, and histology of mucosa-associated lymphoid tissue. Toxicol Pathol, 34, 599–608.
   PubMed Web of Science ®Google Scholar
• Challacombe SJ, Rahman D, Jeffery H, Davis SS, O’Hagan DT. (1992). Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen. Immunology, 76, 164–168.
   PubMed Web of Science ®Google Scholar
• Challacombe SJ, Rahman D, O’Hagan DT. (1997). Salivary, gut, vaginal and nasal antibody responses after oral immunization with biodegradable microparticles. Vaccine, 15, 169–175.
   PubMed Web of Science ®Google Scholar
• Cheng E, Cárdenas-Freytag L, Clements JD. (1999). The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin (LT). Vaccine, 18, 38–49.
   PubMed Web of Science ®Google Scholar
• Clark MA, Jepson MA, Hirst BH. (2001). Exploiting M cells for drug and vaccine delivery. Adv Drug Deliv Rev, 50, 81–106.
   PubMed Web of Science ®Google Scholar
• Clark MA, Jepson MA, Simmons NL, Hirst BH. (1995). Selective binding and transcytosis of Ulex europaeus 1 lectin by mouse Peyer’s patch M-cells in vivo. Cell Tissue Res, 282, 455–461.
   PubMed Web of Science ®Google Scholar
• Clements JD, Finkelstein RA. (1979). Isolation and characterization of homogeneous heat-labile enterotoxins with high specific activity from Escherichia coli cultures. Infect Immun, 24, 760–769.
   PubMed Web of Science ®Google Scholar
• Clements JD, Yancey RJ, Finkelstein RA. (1980). Properties of homogeneous heat-labile enterotoxin from Escherichia coli. Infect Immun, 29, 91–97.
   PubMed Web of Science ®Google Scholar
• Di Colo G, Zambito Y, Burgalassi S, Nardini I, Saettone MF. (2004). Effect of chitosan and of N-carboxymethylchitosan on intraocular penetration of topically applied ofloxacin. Int J Pharm, 273, 37–44.
   PubMed Web of Science ®Google Scholar
• Conway MA, Madrigal-Estebas L, McClean S, Brayden DJ, Mills KH. (2001). Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Th1 and Th2 cells. Vaccine, 19, 1940–1950.
   PubMed Web of Science ®Google Scholar
• Coucke D, Schotsaert M, Libert C, Pringels E, Vervaet C, Foreman P, Saelens X, Remon JP. (2009). Spray-dried powders of starch and crosslinked poly(acrylic acid) as carriers for nasal delivery of inactivated influenza vaccine. Vaccine, 27, 1279–1286.
   PubMed Web of Science ®Google Scholar
• Cranage MP, Fraser CA, Stevens Z, Huting J, Chang M, Jeffs SA, Seaman MS, Cope A, Cole T, Shattock RJ. (2010). Repeated vaginal administration of trimeric HIV-1 clade C gp140 induces serum and mucosal antibody responses. Mucosal Immunol, 3, 57–68.
   PubMed Web of Science ®Google Scholar
• Cuburu N, Kweon MN, Song JH, Hervouet C, Luci C, Sun JB, Hofman P, Holmgren J, Anjuère F, Czerkinsky C. (2007). Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine, 25, 8598–8610.
   PubMed Web of Science ®Google Scholar
• Davis SS. (2006). The use of soluble polymers and polymer microparticles to provide improved vaccine responses after parenteral and mucosal delivery. Vaccine, 24 Suppl 2, S2–S7.
   PubMedGoogle Scholar
• De Koninck P, Archambault D, Hamel F, Sarhan F, Mateescu MA. (2010). Carboxymethyl-starch excipients for gastrointestinal stable oral protein formulations containing protease inhibitors. J Pharm Pharm Sci, 13, 78–92.
   PubMed Web of Science ®Google Scholar
• De Magistris MT. (2006). Mucosal delivery of vaccine antigens and its advantages in pediatrics. Adv Drug Deliv Rev, 58, 52–67.
   PubMed Web of Science ®Google Scholar
• Delgado A, Lavelle EC, Hartshorne M, Davis SS. (1999). PLG microparticles stabilised using enteric coating polymers as oral vaccine delivery systems. Vaccine, 17, 2927–2938.
   PubMed Web of Science ®Google Scholar
• Di Tommaso A, Saletti G, Pizza M, Rappuoli R, Dougan G, Abrignani S, Douce G, De Magistris MT. (1996). Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infect Immun, 64, 974–979.
   PubMed Web of Science ®Google Scholar
• Dodane V, Amin Khan M, Merwin JR. (1999). Effect of chitosan on epithelial permeability and structure. Int J Pharm, 182, 21–32.
   PubMed Web of Science ®Google Scholar
• Durham SR. (2008). Sublingual immunotherapy: what have we learnt from the ‘big trials’? Curr Opin Allergy Clin Immunol, 8, 577–584.
   PubMed Web of Science ®Google Scholar
• Ehreth J. (2003). The global value of vaccination. Vaccine, 21, 596–600.
   PubMed Web of Science ®Google Scholar
• Eldridge JH, Hammond CJ, Meulbroek JA, Staas JK, Gilley RM, Tice TR. (1990). Controlled vaccine release in the gut-associated lymphoid tissues: I. Orally administered biodegradable microspheres target the Peyer’s patches. J.Controlled Release, 11, 205–214.
   Web of Science ®Google Scholar
• Eldridge JH, Meulbroek JA, Staas JK, Tice TR, Gilley RM. (1989). Vaccine-containing biodegradable microspheres specifically enter the gut-associated lymphoid tissue following oral administration and induce a disseminated mucosal immune response. Adv Exp Med Biol, 251, 191–202.
   PubMedGoogle Scholar
• Eldridge JH, Staas JK, Meulbroek JA, Tice TR, Gilley RM. (1991). Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect Immun, 59, 2978–2986.
   PubMed Web of Science ®Google Scholar
• Farraj NF, Johansen BR, Davis SS, Illum L. (1990). Nasal administration of insulin using bioadhesive microspheres as a delivery system. J Control Release, 13, 253–261.
   Web of Science ®Google Scholar
• Florence AT. (2005). Nanoparticle uptake by the oral route: Fulfilling its potential? Drug Dis Today, 2, 75–81.
   Google Scholar
• Foged C, Brodin B, Frokjaer S, Sundblad A. (2005). Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int J Pharm, 298, 315–322.
   PubMed Web of Science ®Google Scholar
• Forstner JF. (1978). Intestinal mucins in health and disease. Digestion, 17, 234–263.
   PubMed Web of Science ®Google Scholar
• Fraser CK, Diener KR, Brown MP, Hayball JD. (2007). Improving vaccines by incorporating immunological coadjuvants. Expert Rev Vaccines, 6, 559–578.
   PubMed Web of Science ®Google Scholar
• Fujihashi K, Koga T, van Ginkel FW, Hagiwara Y, McGhee JR. (2002). A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine, 20, 2431–2438.
   PubMed Web of Science ®Google Scholar
• Fujimura Y, Akisada T, Harada T, Haruma K. (2006). Uptake of microparticles into the epithelium of human nasopharyngeal lymphoid tissue. Med Mol Morphol, 39, 181–186.
   PubMed Web of Science ®Google Scholar
• Galandrini R, De Maria R, Piccoli M, Frati L, Santoni A. (1994a). CD44 triggering enhances human NK cell cytotoxic functions. J Immunol, 153, 4399–4407.
   PubMed Web of Science ®Google Scholar
• Galandrini R, Galluzzo E, Albi N, Grossi CE, Velardi A. (1994b). Hyaluronate is costimulatory for human T cell effector functions and binds to CD44 on activated T cells. J Immunol, 153, 21–31.
   PubMed Web of Science ®Google Scholar
• Garside P, Millington O, Smith KM. (2004). The anatomy of mucosal immune responses. Ann N Y Acad Sci, 1029, 9–15.
   PubMed Web of Science ®Google Scholar
• Ghendon Y, Markushin S, Krivtsov G, Akopova I. (2008). Chitosan as an adjuvant for parenterally administered inactivated influenza vaccines. Arch Virol, 153, 831–837.
   PubMed Web of Science ®Google Scholar
• Giannasca PJ, Giannasca KT, Falk P, Gordon JI, Neutra MR. (1994). Regional differences in glycoconjugates of intestinal M cells in mice: potential targets for mucosal vaccines. Am J Physiol, 267, G1108–G1121.
   PubMed Web of Science ®Google Scholar
• Giannasca PJ, Giannasca KT, Leichtner AM, Neutra MR. (1999). Human intestinal M cells display the sialyl Lewis A antigen. Infect Immun, 67, 946–953.
   PubMed Web of Science ®Google Scholar
• Giuliani MM, Del Giudice G, Giannelli V, Dougan G, Douce G, Rappuoli R, Pizza M. (1998). Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J Exp Med, 187, 1123–1132.
   PubMed Web of Science ®Google Scholar
• Gombotz WR, Wee S. (1998). Protein release from alginate matrices. Adv Drug Deliv Rev, 31, 267–285.
   PubMed Web of Science ®Google Scholar
• Goodsell A, Zhou F, Gupta S, Singh M, Malyala P, Kazzaz J, Greer C, Legg H, Tang T, Zur Megede J, Srivastava R, Barnett SW, Donnelly JJ, Luciw PA, Polo J, O’Hagan DT, Vajdy M. (2008). Beta7-integrin-independent enhancement of mucosal and systemic anti-HIV antibody responses following combined mucosal and systemic gene delivery. Immunology, 123, 378–389.
   PubMed Web of Science ®Google Scholar
• Gupta PN, Khatri K, Goyal AK, Mishra N, Vyas SP. (2007). M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B. J Drug Target, 15, 701–713.
   PubMed Web of Science ®Google Scholar
• Gupta PN, Mahor S, Rawat A, Khatri K, Goyal A, Vyas SP. (2006). Lectin anchored stabilized biodegradable nanoparticles for oral immunization 1. Development and in vitro evaluation. Int J Pharm, 318, 163–173.
   PubMed Web of Science ®Google Scholar
• Gupta S, Zhou F, Greer CE, Legg H, Tang T, Luciw P, zur Megede J, Barnett SW, Donnelly JJ, O’Hagan DT, Polo JM, Vajdy M. (2006). Antibody responses against HIV in rhesus macaques following combinations of mucosal and systemic immunizations with chimeric alphavirus-based replicon particles. AIDS Res Hum Retroviruses, 22, 993–997.
   PubMed Web of Science ®Google Scholar
• Hale C, Humphreys IR, Hussell T, Bowe F, Clare S, Pickard D, Preston A, Del Giudice G, Dougan G. (2004). Mucosal immunisation of murine neonates using whole cell and acellular Pertussis vaccines. Vaccine, 22, 3595–3602.
   PubMed Web of Science ®Google Scholar
• Haltner E, James H, Easson JH, Lehr CM. (1997). Lectins and bacterial invasion factors for controlling endo- and transcytosis of bioadhesive drug carrier systems. Eur J Pharm Biopharm, 44, 3–13
   Web of Science ®Google Scholar
• Hase K, Kawano K, Nochi T, Pontes GS, Fukuda S, Ebisawa M, Kadokura K, Tobe T, Fujimura Y, Kawano S, Yabashi A, Waguri S, Nakato G, Kimura S, Murakami T, Iimura M, Hamura K, Fukuoka S, Lowe AW, Itoh K, Kiyono H, Ohno H. (2009). Uptake through glycoprotein 2 of FimH(+) bacteria by M cells initiates mucosal immune response. Nature, 462, 226–230.
   PubMed Web of Science ®Google Scholar
• Herrero-Vanrell R, Fernandez-Carballido A, Frutos G, Cadórniga R. (2000). Enhancement of the mydriatic response to tropicamide by bioadhesive polymers. J Ocul Pharmacol Ther, 16, 419–428.
   PubMed Web of Science ®Google Scholar
• Hervouet C, Luci C, Cuburu N, Cremel M, Bekri S, Vimeux L, Marañon C, Czerkinsky C, Hosmalin A, Anjuère F. (2010). Sublingual immunization with an HIV subunit vaccine induces antibodies and cytotoxic T cells in the mouse female genital tract. Vaccine, 28, 5582–5590.
   PubMed Web of Science ®Google Scholar
• Heuking S, Adam-Malpel S, Sublet E, Iannitelli A, Stefano A, Borchard G. (2009). Stimulation of human macrophages (THP-1) using Toll-like receptor-2 (TLR-2) agonist decorated nanocarriers. J Drug Target, 17, 662–670.
   PubMed Web of Science ®Google Scholar
• Heuking S, Iannitelli A, Di Stefano A, Borchard G. (2009). Toll-like receptor-2 agonist functionalized biopolymer for mucosal vaccination. Int J Pharm, 381, 97–105.
   PubMed Web of Science ®Google Scholar
• Ho NFH, Barsuhn CL, Burton PS, Merkle HP.(1992). (D) Routes of delivery: Case studies: (3) Mechanistic insights to buccal delivery of proteinaceous substances. Adv Drug Deliv Rev 8, 197–235.
   Web of Science ®Google Scholar
• Holmgren J, Czerkinsky C. (1992). Cholera as a model for research on mucosal immunity and development of oral vaccines. Curr Opin Immunol, 4, 387–391.
   PubMed Web of Science ®Google Scholar
• Holmgren J, Czerkinsky C. (2005). Mucosal immunity and vaccines. Nat Med, 11, S45–S53.
   PubMed Web of Science ®Google Scholar
• Huang CF, Wu TC, Chu YH, Hwang KS, Wang CC, Peng HJ. (2008). Effect of neonatal sublingual vaccination with native or denatured ovalbumin and adjuvant CpG or cholera toxin on systemic and mucosal immunity in mice. Scand J Immunol, 68, 502–510.
   PubMedGoogle Scholar
• Huo Z, Sinha R, McNeela EA, Borrow R, Giemza R, Cosgrove C, Heath PT, Mills KH, Rappuoli R, Griffin GE, Lewis DJ. (2005). Induction of protective serum meningococcal bactericidal and diphtheria-neutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the Neisseria meningitidis serogroup C polysaccharide-CRM197 conjugate vaccine mixed with chitosan. Infect Immun, 73, 8256–8265.
   PubMed Web of Science ®Google Scholar
• Illum L, Farraj NF, Critchley H, Davis SS.(1988). Nasal administration of gentamicin using a novel microsphere delivery system. Int J Pharm, 46, 261–265.
   Web of Science ®Google Scholar
• Illum L, Farraj NF, Davis SS, Johansen BR, O’Hagan DT. (1990). Investigation of the nasal absorption of biosynthetic human growth hormone in sheep – use of a bioadhesive microsphere delivery system. Int J Pharm, 63, 207–211.
   Web of Science ®Google Scholar
• Illum L, Farraj NF, Davis SS. (1994). Chitosan as a novel nasal delivery system for peptide drugs. Pharm Res, 11, 1186–1189.
   PubMed Web of Science ®Google Scholar
• Illum L, Farraj NF, Fisher AN, Gill I., Miglietta M, Benedetti LM. (1994). Hyaluronic acid ester microspheres as a nasal delivery system for insulin. J Control Release, 29, 133–141.
   Web of Science ®Google Scholar
• Illum L, Jabbal-Gill I, Hinchcliffe M, Fisher AN, Davis SS. (2001). Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev, 51, 81–96.
   PubMed Web of Science ®Google Scholar
• Illum L. (1998). Chitosan and its use as a pharmaceutical excipient. Pharm Res, 15, 1326–1331.
   PubMed Web of Science ®Google Scholar
• Iqbal M, Lin W, Jabbal-Gill I, Davis SS, Steward MW, Illum L. (2003). Nasal delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL responses in BALB/c mice. Vaccine, 21, 1478–1485.
   PubMed Web of Science ®Google Scholar
• Jabbal-Gill I, Fisher AN, Rappuoli R, Davis SS, Illum L. (1998). Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice. Vaccine, 16, 2039–2046.
   PubMed Web of Science ®Google Scholar
• Jaganathan KS, Vyas SP. (2006). Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally. Vaccine, 24, 4201–4211.
   PubMed Web of Science ®Google Scholar
• Jakobsen H, Bjarnarson S, Del Giudice G, Moreau M, Siegrist CA, Jonsdottir I. (2002). Intranasal immunization with pneumococcal conjugate vaccines with LT-K63, a nontoxic mutant of heat-Labile enterotoxin, as adjuvant rapidly induces protective immunity against lethal pneumococcal infections in neonatal mice. Infect Immun, 70, 1443–1452.
   PubMed Web of Science ®Google Scholar
• Jani P, McCarthy DE, Florence AT. (1992). Nanosphere and microsphere uptake via Peyer’s patches: observation of the rate of uptake in the rat after a single oral dose. Int J Pharm, 86, 239–246.
   Web of Science ®Google Scholar
• Jepson MA, Clark MA, Hirst BH. (2004). M cell targeting by lectins: a strategy for mucosal vaccination and drug delivery. Adv Drug Deliv Rev, 56, 511–525.
   PubMed Web of Science ®Google Scholar
• Jones DH, Corris S, McDonald S, Clegg JC, Farrar GH. (1997). Poly(DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Vaccine, 15, 814–817.
   PubMed Web of Science ®Google Scholar
• Jones DH, McBride BW, Thornton C, O’Hagan DT, Robinson A, Farrar GH. (1996). Orally administered microencapsulated Bordetella pertussis fimbriae protect mice from B. pertussis respiratory infection. Infect Immun, 64, 489–494.
   PubMed Web of Science ®Google Scholar
• Joseph A, Itskovitz-Cooper N, Samira S, Flasterstein O, Eliyahu H, Simberg D, Goldwaser I, Barenholz Y, Kedar E. (2006). A new intranasal influenza vaccine based on a novel polycationic lipid–ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice. Vaccine, 24, 3990–4006.
   PubMed Web of Science ®Google Scholar
• Josephson L, Tung CH, Moore A, Weissleder R. (1999). High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. Bioconjug Chem, 10, 186–191.
   PubMed Web of Science ®Google Scholar
• Jung T, Kamm W, Breitenbach A, Kaiserling E, Xiao JX, Kissel T. (2000). Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? Eur J Pharm Biopharm, 50, 147–160.
   PubMed Web of Science ®Google Scholar
• Katz DE, DeLorimier AJ, Wolf MK, Hall ER, Cassels FJ, van Hamont JE, Newcomer RL, Davachi MA, Taylor DN, McQueen CE. (2003). Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6 antigen. Vaccine, 21, 341–346.
   PubMed Web of Science ®Google Scholar
• Kazzaz J, Neidleman J, Singh M, Ott G, O’Hagan DT. (2000). Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1. J Control Release, 67, 347–356.
   PubMed Web of Science ®Google Scholar
• Kim B, Bowersock T, Griebel P, Kidane A, Babiuk LA, Sanchez M, Attah-Poku S, Kaushik RS, Mutwiri GK. (2002). Mucosal immune responses following oral immunization with rotavirus antigens encapsulated in alginate microspheres. J Control Release, 85, 191–202.
   PubMed Web of Science ®Google Scholar
• King JC Jr, Lagos R, Bernstein DI, Piedra PA, Kotloff K, Bryant M, Cho I, Belshe RB. (1998). Safety and immunogenicity of low and high doses of trivalent live cold-adapted influenza vaccine administered intranasally as drops or spray to healthy children. J Infect Dis, 177, 1394–1397.
   PubMed Web of Science ®Google Scholar
• Kockisch S, Rees GD, Young SA, Tsibouklis J, Smart JD. (2003). Polymeric microspheres for drug delivery to the oral cavity: an in vitro evaluation of mucoadhesive potential. J Pharm Sci, 92, 1614–1623.
   PubMed Web of Science ®Google Scholar
• Köping-Höggård M, Sánchez A, Alonso MJ. (2005). Nanoparticles as carriers for nasal vaccine delivery. Expert Rev Vaccines, 4, 185–196.
   PubMed Web of Science ®Google Scholar
• Kotzé AF, Thanou MM, Luessen HL, de Boer BG, Verhoef JC, Junginger HE. (1999). Effect of the degree of quaternization of N-trimethyl chitosan chloride on the permeability of intestinal epithelial cells (Caco-2). Eur J Pharm Biopharm, 47, 269–274.
   PubMed Web of Science ®Google Scholar
• Kuolee R, Chen W. (2008). M cell-targeted delivery of vaccines and therapeutics. Expert Opin Drug Deliv, 5, 693–702.
   PubMed Web of Science ®Google Scholar
• Kweon MN, Yamamoto M, Watanabe F, Tamura S, Van Ginkel FW, Miyauchi A, Takagi H, Takeda Y, Hamabata T, Fujihashi K, McGhee JR, Kiyono H. (2002). A nontoxic chimeric enterotoxin adjuvant induces protective immunity in both mucosal and systemic compartments with reduced IgE antibodies. J Infect Dis, 186, 1261–1269.
   PubMed Web of Science ®Google Scholar
• Lambert JS, Keefer M, Mulligan MJ, Schwartz D, Mestecky J, Weinhold K, Smith C, Hsieh R, Moldoveanu Z, Fast P, Forrest B, Koff W. (2001). A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects. Vaccine, 19, 3033–3042.
   PubMed Web of Science ®Google Scholar
• Lanzavecchia A. (1996). Mechanisms of antigen uptake for presentation. Curr Opin Immunol, 8, 348–354.
   PubMed Web of Science ®Google Scholar
• Lavelle EC, Grant G, Pfuller U, O’Hagan DT. (2004). Immunological implications of the use of plant lectins for drug and vaccine targeting to the gastrointestinal tract. J Drug Target, 12, 89–95.
   PubMed Web of Science ®Google Scholar
• Lavelle EC, Grant G, Pusztai A, Pfüller U, Leavy O, McNeela E, Mills KH, O’Hagan DT. (2002). Mistletoe lectins enhance immune responses to intranasally co-administered herpes simplex virus glycoprotein D2. Immunology, 107, 268–274.
   PubMed Web of Science ®Google Scholar
• Lavelle EC, Grant G, Pusztai A, Pfüller U, O’Hagan DT. (2000). Mucosal immunogenicity of plant lectins in mice. Immunology, 99, 30–37.
   PubMed Web of Science ®Google Scholar
• Lavelle EC, Grant G, Pusztai A, Pfüller U, O’Hagan DT. (2001). The identification of plant lectins with mucosal adjuvant activity. Immunology, 102, 77–86.
   PubMed Web of Science ®Google Scholar
• Lavelle EC, O’Hagan DT. (2006). Delivery systems and adjuvants for oral vaccines. Expert Opin Drug Deliv, 3, 747–762.
   PubMed Web of Science ®Google Scholar
• Lee JW, Park JH, Robinson JR. (2000). Bioadhesive-based dosage forms: the next generation. J Pharm Sci, 89, 850–866.
   PubMed Web of Science ®Google Scholar
• Lehr CM, Poelma FCG, Junginger HE, Tukker JJ. (1991). An estimate of turnover time of intestinal mucus gel layer in the rat in situ loop. Int J Pharm, 70, 235–240.
   Web of Science ®Google Scholar
• Lemiale F, Kong WP, Akyürek LM, Ling X, Huang Y, Chakrabarti BK, Eckhaus M, Nabel GJ. (2003). Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J Virol, 77, 10078–10087.
   PubMed Web of Science ®Google Scholar
• Levine MM. (2003). Can needle-free administration of vaccines become the norm in global immunization? Nat Med, 9, 99–103.
   PubMed Web of Science ®Google Scholar
• Lewis DJ, Huo Z, Barnett S, Kromann I, Giemza R, Galiza E, Woodrow M, Thierry-Carstensen B, Andersen P, Novicki D, Del Giudice G, Rappuoli R. (2009). Transient facial nerve paralysis (Bell’s palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS ONE, 4, e6999.
   PubMed Web of Science ®Google Scholar
• Luessen HL, de Leeuw BJ, Langemeÿer MW, de Boer AB, Verhoef JC, Junginger HE. (1996). Mucoadhesive polymers in peroral peptide drug delivery. VI. Carbomer and chitosan improve the intestinal absorption of the peptide drug buserelin in vivo. Pharm Res, 13, 1668–1672.
   PubMed Web of Science ®Google Scholar
• Luessen HL, Rentel CO, Kotzé AF, Lehr CM, de Boer AG, Verhoef JC, Junginger HE. (1997). Mucoadhesive polymers in peroral peptide drug delivery: IV. Polycarbophil and chitosan are potent enhancers of peptide transport across intestinal mucosae in vitro. J Control Release, 45, 15–23.
   Web of Science ®Google Scholar
• Lutsiak ME, Robinson DR, Coester C, Kwon GS, Samuel J. (2002). Analysis of poly(D,L-lactic-co-glycolic acid) nanosphere uptake by human dendritic cells and macrophages in vitro. Pharm Res, 19, 1480–1487.
   PubMed Web of Science ®Google Scholar
• Maloy KJ, Donachie AM, O’Hagan DT, Mowat AM. (1994). Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. Immunology, 81, 661–667.
   PubMed Web of Science ®Google Scholar
• Manocha M, Pal PC, Chitralekha KT, Thomas BE, Tripathi V, Gupta SD, Paranjape R, Kulkarni S, Rao DN. (2005). Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target. Vaccine, 23, 5599–5617.
   PubMed Web of Science ®Google Scholar
• Mantis NJ, Frey A, Neutra MR. (2000). Accessibility of glycolipid and oligosaccharide epitopes on rabbit villus and follicle-associated epithelium. Am J Physiol Gastrointest Liver Physiol, 278, G915–G923.
   PubMed Web of Science ®Google Scholar
• Marinaro M, Riccomi A, Rappuoli R, Pizza M, Fiorelli V, Tripiciano A, Cafaro A, Ensoli B, De Magistris MT. (2003). Mucosal delivery of the human immunodeficiency virus-1 Tat protein in mice elicits systemic neutralizing antibodies, cytotoxic T lymphocytes and mucosal IgA. Vaccine, 21, 3972–3981.
   PubMed Web of Science ®Google Scholar
• Marx PA, Compans RW, Gettie A, Staas JK, Gilley RM, Mulligan MJ, Yamshchikov GV, Chen D, Eldridge JH. (1993). Protection against vaginal SIV transmission with microencapsulated vaccine. Science, 260, 1323–1327.
   PubMed Web of Science ®Google Scholar
• Mathiowitz E, Jacob JS, Jong YS, Carino GP, Chickering DE, Chaturvedi P, Santos CA, Vijayaraghavan K, Montgomery S, Bassett M, Morrell C. (1997). Biologically erodable microspheres as potential oral drug delivery systems. Nature, 386, 410–414.
   PubMed Web of Science ®Google Scholar
• McNeela EA, Jabbal-Gill I, Illum L, Pizza M, Rappuoli R, Podda A, Lewis DJ, Mills KH. (2004). Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan. Vaccine, 22, 909–914.
   PubMed Web of Science ®Google Scholar
• McNeela EA, O’Connor D, Jabbal-Gill I, Illum L, Davis SS, Pizza M, Peppoloni S, Rappuoli R, Mills KH. (2000). A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. Vaccine, 19, 1188–1198.
   PubMed Web of Science ®Google Scholar
• Mills KH, Cosgrove C, McNeela EA, Sexton A, Giemza R, Jabbal-Gill I, Church A, Lin W, Illum L, Podda A, Rappuoli R, Pizza M, Griffin GE, Lewis DJ. (2003). Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin a. Infect Immun, 71, 726–732.
   PubMed Web of Science ®Google Scholar
• Mitragotri S. (2005). Immunization without needles. Nat Rev Immunol, 5, 905–916.
   PubMed Web of Science ®Google Scholar
• Miyoshi J, Takai Y. (2005). Molecular perspective on tight-junction assembly and epithelial polarity. Adv Drug Deliv Rev, 57, 815–855.
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Hawley AE, Christy NM, Gray T, Illum L, Davis SS. (1994). Surface engineered nanospheres with enhanced drainage into lymphatics and uptake by macrophages of the regional lymph nodes. FEBS Lett, 344, 25–30.
   PubMed Web of Science ®Google Scholar
• Mohapatra SS. (2003). Mucosal gene expression vaccine: a novel vaccine strategy for respiratory syncytial virus. Pediatr Infect Dis J, 22, S100–3; discussion S103.
   PubMed Web of Science ®Google Scholar
• Moore A, McGuirk P, Adams S, Jones WC, McGee JP, O’Hagan DT, Mills KH. (1995). Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells. Vaccine, 13, 1741–1749.
   PubMed Web of Science ®Google Scholar
• Mottram PL, Leong D, Crimeen-Irwin B, Gloster S, Xiang SD, Meanger J, Ghildyal R, Vardaxis N, Plebanski M. (2007). Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus. Mol Pharm, 4, 73–84.
   PubMed Web of Science ®Google Scholar
• Mulhbacher J, Ispas-Szabo P, Mateescu MA. (2004). Cross-linked high amylose starch derivatives for drug release. II. Swelling properties and mechanistic study. Int J Pharm, 278, 231–238.
   PubMed Web of Science ®Google Scholar
• Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, Spyr C, Steffen R. (2004). Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. N Engl J Med, 350, 896–903.
   PubMed Web of Science ®Google Scholar
• Muzzarelli RA, Mattioli-Belmonte M, Pugnaloni A, Biagini G. (1999). Biochemistry, histology and clinical uses of chitins and chitosans in wound healing. EXS, 87, 251–264.
   PubMedGoogle Scholar
• Nagamoto T, Hattori Y, Takayama K, Maitani Y. (2004). Novel chitosan particles and chitosan-coated emulsions inducing immune response via intranasal vaccine delivery. Pharm Res, 21, 671–674.
   PubMed Web of Science ®Google Scholar
• Negri DR, Riccomi A, Pinto D, Vendetti S, Rossi A, Cicconi R, Ruggiero P, Del Giudice G, De Magistris MT. (2010). Persistence of mucosal and systemic immune responses following sublingual immunization. Vaccine, 28, 4175–4180.
   Google Scholar
• Neidleman JA, Vajdy M, Ugozzoli M, Ott G, O’Hagan D. (2000). Genetically detoxified mutants of heat-labile enterotoxin from Escherichia coli are effective adjuvants for induction of cytotoxic T-cell responses against HIV-1 gag-p55. Immunology, 101, 154–160.
   PubMed Web of Science ®Google Scholar
• Neutra MR, Frey A, Kraehenbuhl JP. (1996). Epithelial M cells: gateways for mucosal infection and immunization. Cell, 86, 345–348.
   PubMed Web of Science ®Google Scholar
• Neutra MR, Kozlowski PA. (2006). Mucosal vaccines: the promise and the challenge. Nat Rev Immunol, 6, 148–158.
   PubMed Web of Science ®Google Scholar
• Newman KD, Elamanchili P, Kwon GS, Samuel J. (2002). Uptake of poly(D,L-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo. J Biomed Mater Res, 60, 480–486.
   PubMed Web of Science ®Google Scholar
• Nishimura K, Nishimura S, Nishi N, Numata F, Tone Y, Tokura S, Azuma I. (1985). Adjuvant activity of chitin derivatives in mice and guinea-pigs. Vaccine, 3, 379–384.
   PubMed Web of Science ®Google Scholar
• Nishimura K, Nishimura S, Nishi N, Saiki I, Tokura S, Azuma I. (1984). Immunological activity of chitin and its derivatives. Vaccine, 2, 93–99.
   PubMedGoogle Scholar
• Nixon DF, Hioe C, Chen PD, Bian Z, Kuebler P, Li ML, Qiu H, Li XM, Singh M, Richardson J, McGee P, Zamb T, Koff W, Wang CY, O’Hagan D. (1996). Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. Vaccine, 14, 1523–1530.
   PubMed Web of Science ®Google Scholar
• Nochi T, Yuki Y, Matsumura A, Mejima M, Terahara K, Kim DY, Fukuyama S, Iwatsuki-Horimoto K, Kawaoka Y, Kohda T, Kozaki S, Igarashi O, Kiyono H. (2007). A novel M cell-specific carbohydrate-targeted mucosal vaccine effectively induces antigen-specific immune responses. J Exp Med, 204, 2789–2796.
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Jeffery H, Roberts MJ, McGee JP, Davis SS. (1991). Controlled release microparticles for vaccine development. Vaccine, 9, 768–771.
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Jeffery H, Davis SS. (1993). Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles. Vaccine, 11, 965–969.
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Valiante NM. (2003). Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov, 2, 727–735.
   PubMed Web of Science ®Google Scholar
• O’Hagan DT. (1998). Microparticles and polymers for the mucosal delivery of vaccines. Adv Drug Deliv Rev, 34, 305–320.
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Palin K, Davis SS, Artursson P, Sjöholm I. (1989a). Microparticles as potentially orally active immunological adjuvants. Vaccine, 7, 421–424.
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Palin KJ, Davis SS. (1989b). Poly(butyl-2-cyanoacrylate) particles as adjuvants for oral immunization. Vaccine, 7, 213–216.
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Rafferty D, Wharton S, Illum L. (1993). Intravaginal immunization in sheep using a bioadhesive microsphere antigen delivery system. Vaccine, 11, 660–664.
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Rahman D, McGee JP, Jeffery H, Davies MC, Williams P, Davis SS, Challacombe SJ. (1991). Biodegradable microparticles as controlled release antigen delivery systems. Immunology, 73, 239–242.
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Rappuoli R. (2006). Novel approaches to pediatric vaccine delivery. Adv Drug Deliv Rev, 58, 29–51.
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Singh M. (2003). Microparticles as vaccine adjuvants and delivery systems. Expert Rev Vaccines, 2, 269–283.
   PubMedGoogle Scholar
• O’Hagan DT. (1996). The intestinal uptake of particles and the implications for drug and antigen delivery. J Anat, 189 (Pt 3), 477–482.
   PubMedGoogle Scholar
• Okada H, Toguchi H. (1995). Biodegradable microspheres in drug delivery. Crit Rev Ther Drug Carrier Syst, 12, 1–99.
   PubMed Web of Science ®Google Scholar
• Otten G, Schaefer M, Greer C, Calderon-Cacia M, Coit D, Kazzaz J, Medina-Selby A, Selby M, Singh M, Ugozzoli M, zur Megede J, Barnett SW, O’Hagan D, Donnelly J, Ulmer J. (2003). Induction of broad and potent anti-human immunodeficiency virus immune responses in rhesus macaques by priming with a DNA vaccine and boosting with protein-adsorbed polylactide coglycolide microparticles. J Virol, 77, 6087–6092.
   PubMed Web of Science ®Google Scholar
• Otterlei M, Vårum KM, Ryan L, Espevik T. (1994). Characterization of binding and TNF-alpha-inducing ability of chitosans on monocytes: the involvement of CD14. Vaccine, 12, 825–832.
   PubMed Web of Science ®Google Scholar
• Palma C, Iona E, Giannoni F, Pardini M, Brunori L, Fattorini L, Del Giudice G, Cassone A. (2008). The LTK63 adjuvant improves protection conferred by Ag85B DNA-protein prime-boosting vaccination against Mycobacterium tuberculosis infection by dampening IFN-gamma response. Vaccine, 26, 4237–4243.
   PubMed Web of Science ®Google Scholar
• Partidos CD, Pizza M, Rappuoli R, Steward MW. (1996). The adjuvant effect of a non-toxic mutant of heat-labile enterotoxin of Escherichia coli for the induction of measles virus-specific CTL responses after intranasal co-immunization with a synthetic peptide. Immunology, 89, 483–487.
   PubMed Web of Science ®Google Scholar
• Passalacqua G, Canonica GW. (2006). Sublingual immunotherapy: update 2006. Curr Opin Allergy Clin Immunol, 6, 449–454.
   PubMed Web of Science ®Google Scholar
• Pediatrics. (1997). Alternative routes of drug administration—advantages and disadvantages (subject review). American Academy of Pediatrics. Committee on Drugs. Pediatrics 100:143-152. http://aappolicy.aappublications.org/cgi/content/full/pediatrics; 100/1/143 (Accessed 28 September 2010)
   Google Scholar
• Peluso G, Petillo O, Ranieri M, Santin M, Ambrosio L, Calabró D, Avallone B, Balsamo G. (1994). Chitosan-mediated stimulation of macrophage function. Biomaterials, 15, 1215–1220.
   PubMed Web of Science ®Google Scholar
• Piedra PA, Yan L, Kotloff K, Zangwill K, Bernstein DI, King J, Treanor J, Munoz F, Wolff M, Cho I, Mendelman PM, Cordova J, Belshe RB. (2002). Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children. Pediatrics, 110, 662–672.
   PubMed Web of Science ®Google Scholar
• Pizza M, Domenighini M, Hol W, Giannelli V, Fontana MR, Giuliani MM, Magagnoli C, Peppoloni S, Manetti R, Rappuoli R. (1994a). Probing the structure-activity relationship of Escherichia coli LT-A by site-directed mutagenesis. Mol Microbiol, 14, 51–60.
   PubMed Web of Science ®Google Scholar
• Pizza M, Fontana MR, Giuliani MM, Domenighini M, Magagnoli C, Giannelli V, Nucci D, Hol W, Manetti R, Rappuoli R. (1994b). A genetically detoxified derivative of heat-labile Escherichia coli enterotoxin induces neutralizing antibodies against the A subunit. J Exp Med, 180, 2147–2153.
   PubMed Web of Science ®Google Scholar
• Pizza M, Giuliani MM, Fontana MR, Monaci E, Douce G, Dougan G, Mills KH, Rappuoli R, Del Giudice G. (2001). Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine, 19, 2534–2541.
   PubMed Web of Science ®Google Scholar
• Porgador A, Staats HF, Faiola B, Gilboa E, Palker TJ. (1997). Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo. J Immunol, 158, 834–841.
   PubMed Web of Science ®Google Scholar
• Porporatto C, Bianco ID, Correa SG. (2005). Local and systemic activity of the polysaccharide chitosan at lymphoid tissues after oral administration. J Leukoc Biol, 78, 62–69.
   PubMed Web of Science ®Google Scholar
• Putney SD, Burke PA. (1998). Improving protein therapeutics with sustained-release formulations. Nat Biotechnol, 16, 153–157.
   PubMed Web of Science ®Google Scholar
• Rappuoli R, Pizza M, Douce G, Dougan G. (1999). Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol Today, 20, 493–500.
   PubMedGoogle Scholar
• Read RC, Naylor SC, Potter CW, Bond J, Jabbal-Gill I, Fisher A, Illum L, Jennings R. (2005). Effective nasal influenza vaccine delivery using chitosan. Vaccine, 23, 4367–4374.
   PubMed Web of Science ®Google Scholar
• Rebelatto MC, Guimond P, Bowersock TL, HogenEsch H. (2001). Induction of systemic and mucosal immune response in cattle by intranasal administration of pig serum albumin in alginate microparticles. Vet Immunol Immunopathol, 83, 93–105.
   PubMed Web of Science ®Google Scholar
• Reis e Sousa C, Stahl PD, Austyn JM. (1993). Phagocytosis of antigens by Langerhans cells in vitro. J Exp Med, 178, 509–519.
   PubMed Web of Science ®Google Scholar
• Richardson J, Ramires P, Miglietta M, Rochira L, Bacella L, Callegaro L, Benedetti L. (1995). Novel vaginal delivery systems for calcitonin: I. Evaluation of HYAFF/calcitonin microspheres in rats. Int J Pharm, 115, 9–15.
   Web of Science ®Google Scholar
• Romero JF, Ciabattini A, Guillaume P, Frank G, Ruggiero P, Pettini E, Del Giudice G, Medaglini D, Corradin G. (2009). Intranasal administration of the synthetic polypeptide from the C-terminus of the circumsporozoite protein of Plasmodium berghei with the modified heat-labile toxin of Escherichia coli (LTK63) induces a complete protection against malaria challenge. Vaccine, 27, 1266–1271.
   PubMed Web of Science ®Google Scholar
• Roper H. (2001). Applications of starch and its derivatives. Carbohydr Eur, 15, 14–21.
   Google Scholar
• Roy K, Mao HQ, Huang SK, Leong KW. (1999). Oral gene delivery with chitosan–DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med, 5, 387–391.
   PubMed Web of Science ®Google Scholar
• Roy SK, Prabhakar B. (2010). Bioadhesive Polymeric Platforms for Transmucosal Drug Delivery Systems – a Review. Trop J Pharm Res, 9, 91–104.
   Web of Science ®Google Scholar
• Ryan EJ, McNeela E, Murphy GA, Stewart H, O’hagan D, Pizza M, Rappuoli R, Mills KH. (1999). Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells. Infect Immun, 67, 6270–6280.
   PubMed Web of Science ®Google Scholar
• Rydell N, Stertman L, Sjöholm I. (2005). Starch microparticles as vaccine adjuvant. Expert Opin Drug Deliv, 2, 807–828.
   PubMedGoogle Scholar
• Rydell N, Stertman L, Stålenheim G, Sjöholm I. (2006). Use of an oral diphtheria vaccine in human. Vaccine, 24, 5928–5930.
   PubMed Web of Science ®Google Scholar
• Salamat-Miller N, Chittchang M, Johnston TP. (2005). The use of mucoadhesive polymers in buccal drug delivery. Adv Drug Deliv Rev, 57, 1666–1691.
   PubMed Web of Science ®Google Scholar
• Sallusto F, Cella M, Danieli C, Lanzavecchia A. (1995). Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med, 182, 389–400.
   PubMed Web of Science ®Google Scholar
• Sandri G, Bonferoni MC, Rossi S, Ferrari F, Gibin S, Zambito Y, Di Colo G, Caramella C. (2007). Nanoparticles based on N-trimethylchitosan: evaluation of absorption properties using in vitro (Caco-2 cells) and ex vivo (excised rat jejunum) models. Eur J Pharm Biopharm, 65, 68–77.
   PubMed Web of Science ®Google Scholar
• Sandri G, Rossi S, Ferrari F, Bonferoni MC, Muzzarelli C, Caramella C. (2004). Assessment of chitosan derivatives as buccal and vaginal penetration enhancers. Eur J Pharm Sci, 21, 351–359.
   PubMed Web of Science ®Google Scholar
• Sayin B, Somavarapu S, Li XW, Sesardic D, Senel S, Alpar OH. (2009). TMC-MCC (N-trimethyl chitosan-mono-N-carboxymethyl chitosan) nanocomplexes for mucosal delivery of vaccines. Eur J Pharm Sci, 38, 362–369.
   PubMed Web of Science ®Google Scholar
• Sayin B, Somavarapu S, Li XW, Thanou M, Sesardic D, Alpar HO, Senel S. (2008). Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery. Int J Pharm, 363, 139–148.
   PubMed Web of Science ®Google Scholar
• Schipper NG, Olsson S, Hoogstraate JA, deBoer AG, Vårum KM, Artursson P. (1997). Chitosans as absorption enhancers for poorly absorbable drugs 2: mechanism of absorption enhancement. Pharm Res, 14, 923–929.
   PubMed Web of Science ®Google Scholar
• Shahin R, Leef M, Eldridge J, Hudson M, Gilley R. (1995). Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly(DL-lactide-co-glycolide) microspheres. Infect Immun, 63, 1195–1200.
   PubMed Web of Science ®Google Scholar
• Shakweh M, Besnard M, Nicolas V, Fattal E. (2005). Poly (lactide-co-glycolide) particles of different physicochemical properties and their uptake by peyer’s patches in mice. Eur J Pharm Biopharm, 61, 1–13.
   PubMed Web of Science ®Google Scholar
• Sharma R, Schumacher U, Adam E. (1998). Lectin histochemistry reveals the appearance of M-cells in Peyer’s patches of SCID mice after syngeneic normal bone marrow transplantation. J Histochem Cytochem, 46, 143–148.
   PubMed Web of Science ®Google Scholar
• Sieval AB, Thanou M, Kotzé AF, Verhoef JC, Brussee J, Junginger HE. (1998). Preparation and NMR characterization of highly substituted N-trimethyl chitosan chloride. Carbohydr Polym, 36, 157–165.
   Web of Science ®Google Scholar
• Simmons CP, Mastroeni P, Fowler R, Ghaem-maghami M, Lycke N, Pizza M, Rappuoli R, Dougan G. (1999). MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants. J Immunol, 163, 6502–6510.
   PubMed Web of Science ®Google Scholar
• Singh M, Briones M, O’Hagan D. Hyaluronic acid biopolymers for mucosal delivery of vaccines. In New Frontiers in Medical Sciences: Redefining Hyaluronan, Abatangelo, G. & Weigel, P.H., Eds., Elsevier Science, Amsterdam, 2000, pp. 163–170.
   Google Scholar
• Singh M, Briones M, O’Hagan DT. (2001). A novel bioadhesive intranasal delivery system for inactivated influenza vaccines. J Control Release, 70, 267–276.
   PubMed Web of Science ®Google Scholar
• Singh M, Kazzaz J, Chesko J, Soenawan E, Ugozzoli M, Giuliani M, Pizza M, Rappouli R, O’Hagan DT. (2004). Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B. J Pharm Sci, 93, 273–282.
   PubMed Web of Science ®Google Scholar
• Singh M, Vajdy M, Gardner J, Briones M, O’Hagan D. (2001). Mucosal immunization with HIV-1 gag DNA on cationic microparticles prolongs gene expression and enhances local and systemic immunity. Vaccine, 20, 594–602.
   PubMed Web of Science ®Google Scholar
• Smart JD. (2005a). Buccal drug delivery. Expert Opin Drug Deliv, 2, 507–517.
   PubMedGoogle Scholar
• Smart JD. (2005b). The basics and underlying mechanisms of mucoadhesion. Adv Drug Deliv Rev, 57, 1556–1568.
   PubMed Web of Science ®Google Scholar
• Song JH, Kim JI, Kwon HJ, Shim DH, Parajuli N, Cuburu N, Czerkinsky C, Kweon MN. (2009). CCR7-CCL19/CCL21-regulated dendritic cells are responsible for effectiveness of sublingual vaccination. J Immunol, 182, 6851–6860.
   PubMed Web of Science ®Google Scholar
• Song JH, Nguyen HH, Cuburu N, Horimoto T, Ko SY, Park SH, Czerkinsky C, Kweon MN. (2008). Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc Natl Acad Sci USA, 105, 1644–1649.
   PubMed Web of Science ®Google Scholar
• Stephenson I, Zambon MC, Rudin A, Colegate A, Podda A, Bugarini R, Del Giudice G, Minutello A, Bonnington S, Holmgren J, Mills KH, Nicholson KG. (2006). Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J Virol, 80, 4962–4970.
   PubMed Web of Science ®Google Scholar
• Stertman L, Lundgren E, Sjöholm I. (2006). Starch microparticles as a vaccine adjuvant: only uptake in Peyer’s patches decides the profile of the immune response. Vaccine, 24, 3661–3668.
   PubMed Web of Science ®Google Scholar
• Stertman L, Strindelius L, Sjöholm I. (2004). Starch microparticles as an adjuvant in immunisation: effect of route of administration on the immune response in mice. Vaccine, 22, 2863–2872.
   PubMed Web of Science ®Google Scholar
• Sun H, Pan H, Yang Z, Shi M. (2007). The immune response and protective efficacy of vaccination with oral microparticle Aeromonas sobria vaccine in mice. Int Immunopharmacol, 7, 1259–1264.
   PubMed Web of Science ®Google Scholar
• Sun JB, Eriksson K, Li BL, Lindblad M, Azem J, Holmgren J. (2004). Vaccination with dendritic cells pulsed in vitro with tumor antigen conjugated to cholera toxin efficiently induces specific tumoricidal CD8+ cytotoxic lymphocytes dependent on cyclic AMP activation of dendritic cells. Clin Immunol, 112, 35–44.
   PubMed Web of Science ®Google Scholar
• Tacken PJ, de Vries IJ, Gijzen K, Joosten B, Wu D, Rother RP, Faas SJ, Punt CJ, Torensma R, Adema GJ, Figdor CG. (2005). Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood, 106, 1278–1285.
   PubMed Web of Science ®Google Scholar
• Tacket CO, Reid RH, Boedeker EC, Losonsky G, Nataro JP, Bhagat H, Edelman R. (1994). Enteral immunization and challenge of volunteers given enterotoxigenic E. coli CFA/II encapsulated in biodegradable microspheres. Vaccine, 12, 1270–1274.
   PubMed Web of Science ®Google Scholar
• Tafaghodi M, Rastegar S. (2010). Preparation and in vivo study of dry powder microspheres for nasal immunization. J Drug Target, 18, 235–242.
   PubMed Web of Science ®Google Scholar
• Tafaghodi M, Sajadi Tabasi SA, Jaafari MR. (2006). Formulation, characterization and release studies of alginate microspheres encapsulated with tetanus toxoid. J Biomater Sci Polym Ed, 17, 909–924.
   PubMed Web of Science ®Google Scholar
• Takeuchi H, Matsui Y, Yamamoto H, Kawashima Y. (2003). Mucoadhesive properties of carbopol or chitosan-coated liposomes and their effectiveness in the oral administration of calcitonin to rats. J Control Release, 86, 235–242.
   PubMed Web of Science ®Google Scholar
• Tamura SI, Kurata T. (2000). A proposal for safety standards for human use of cholera toxin (or Escherichia coli heat-labile enterotoxin) derivatives as an adjuvant of nasal inactivated influenza vaccine. Jpn J Infect Dis, 53, 98–106.
   PubMed Web of Science ®Google Scholar
• Thanou M, Verhoef JC, Junginger HE. (2001). Oral drug absorption enhancement by chitosan and its derivatives. Adv Drug Deliv Rev, 52, 117–126.
   PubMed Web of Science ®Google Scholar
• Thanou MM, Verhoef JC, Romeijn SG, Nagelkerke JF, Merkus FW, Junginger HE. (1999). Effects of N-trimethyl chitosan chloride, a novel absorption enhancer, on caco-2 intestinal epithelia and the ciliary beat frequency of chicken embryo trachea. Int J Pharm, 185, 73–82.
   PubMed Web of Science ®Google Scholar
• Tharanathan RN, Kittur FS. (2003). Chitin–the undisputed biomolecule of great potential. Crit Rev Food Sci Nutr, 43, 61–87.
   PubMed Web of Science ®Google Scholar
• Thiele L, Merkle HP, Walter E. (2003). Phagocytosis and phagosomal fate of surface-modified microparticles in dendritic cells and macrophages. Pharm Res, 20, 221–228.
   PubMed Web of Science ®Google Scholar
• Tseng J, Komisar JL, Trout RN, Hunt RE, Chen JY, Johnson AJ, Pitt L, Ruble DL. (1995). Humoral immunity to aerosolized staphylococcal enterotoxin B (SEB), a superantigen, in monkeys vaccinated with SEB toxoid-containing microspheres. Infect Immun, 63, 2880–2885.
   PubMed Web of Science ®Google Scholar
• Ugozzoli M, Mariani M, Del Giudice G, Soenawan E, O’Hagan DT. (2002). Combinations of protein polysaccharide conjugate vaccines for intranasal immunization. J Infect Dis, 186, 1358–1361.
   PubMed Web of Science ®Google Scholar
• Ugozzoli M, O’Hagan DT, Ott GS. (1998). Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: the effect of adjuvants on mucosal and serum antibody responses. Immunology, 93, 563–571.
   PubMed Web of Science ®Google Scholar
• Ugozzoli M, Santos G, Donnelly J, O’Hagan DT. (2001). Potency of a genetically detoxified mucosal adjuvant derived from the heat-labile enterotoxin of Escherichia coli (LTK63) is not adversely affected by the presence of preexisting immunity to the adjuvant. J Infect Dis, 183, 351–354.
   PubMed Web of Science ®Google Scholar
• Vajdy M. (2007). Mucosal adjuvants and delivery systems. Vaccine Adjuvants and Delivery Systems, Edited by Manmohan Singh Copyright © 2007 John Wiley & Sons, Inc. (p 295–326).
   Google Scholar
• van der Lubben IM, van Opdorp FA, Hengeveld MR, Onderwater JJ, Koerten HK, Verhoef JC, Borchard G, Junginger HE. (2002). Transport of chitosan microparticles for mucosal vaccine delivery in a human intestinal M-cell model. J Drug Target, 10, 449–456.
   PubMed Web of Science ®Google Scholar
• van Ginkel FW, Jackson RJ, Yuki Y, McGhee JR. (2000). Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol, 165, 4778–4782.
   PubMed Web of Science ®Google Scholar
• Vasir JK, Tambwekar K, Garg S. (2003). Bioadhesive microspheres as a controlled drug delivery system. Int J Pharm, 255, 13–32.
   PubMed Web of Science ®Google Scholar
• Vila A, Sánchez A, Evora C, Soriano I, McCallion O, Alonso MJ. (2005). PLA-PEG particles as nasal protein carriers: the influence of the particle size. Int J Pharm, 292, 43–52.
   PubMed Web of Science ®Google Scholar
• Whittum-Hudson JA, An LL, Saltzman WM, Prendergast RA, MacDonald AB. (1996). Oral immunization with an anti-idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection. Nat Med, 2, 1116–1121.
   PubMed Web of Science ®Google Scholar
• Wilson DR, Lima MT, Durham SR. (2005). Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy, 60, 4–12.
   PubMed Web of Science ®Google Scholar
• Xiang SD, Scholzen A, Minigo G, David C, Apostolopoulos V, Mottram PL, Plebanski M. (2006). Pathogen recognition and development of particulate vaccines: does size matter? Methods, 40, 1–9.
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Takeda Y, Yamamoto M, Kurazono H, Imaoka K, Yamamoto M, Fujihashi K, Noda M, Kiyono H, McGhee JR. (1997). Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity. J Exp Med, 185, 1203–1210.
   PubMed Web of Science ®Google Scholar
• Yuki Y, Kiyono H. (2009). Mucosal vaccines: novel advances in technology and delivery. Expert Rev Vaccines, 8, 1083–1097.
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhang J, Streisand JB. (2002). Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications. Clin Pharmacokinet, 41, 661–680.
   PubMed Web of Science ®Google Scholar